Upadacitinib is a potent, selective, reversible, ATP-competitive JAK1 inhibitor. It affects JAK/STAT and NF-κB signaling pathways by binding to the kinase catalytic domain and blocking STAT phosphorylation, effectively inhibiting inflammatory responses and cytokine production.
ABT-494 (Upadacitinib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for ABT-494 (Upadacitinib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.